| Abstract |
Gliomas are the most malignant and aggressive brain tumor with poor prognosis. The existence of glioma stem cells (GSCs) which capable of self-renewal, and multilineage differentiation contributes to tumor initiation and therapeutic resistance of gliomas. Targeting cancer stem cell marker of GSCs have been purposed as an effective strategy for treatment of gliomas. Many glycans and glycoproteins, such as CD133 and CD44, were identified as cancer stem cell markers. In our study, a lectin isolated from Butea monosperma seeds, namely Butea monosperma agglutinin (BMA), was used for detection of BMA-binding glycan (BMAG) in GSCs and the differentiated malignant glioma cells. Lectincytofluorescent staining showed that BMAG was strongly expressed in GSCs; GSC-03A, GSC-03U, GSC-07U, U373-GSC; and it was faintly expressed in differentiated malignant glioma cells. This information suggested the potential of using BMAG as a GSC marker. However, the role of BMAG on stemness maintenance and/or differentiation of GSCs is needed to be further explored. The data on functional analyses of BMAG in GSCs and its potential as a target for glioma treatment will be presented. |
Publication
Journal Publication
ไทย